Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 4830

Next Previous
Drug Profile

MK 4830

Alternative Names: MK-4830

Latest Information Update: 08 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agenus
  • Developer Merck Sharp & Dohme; Presage Biosciences
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; LILRB2 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I/II Oesophageal cancer
  • No development reported Head and neck cancer; Soft tissue sarcoma
  • Discontinued Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours

Most Recent Events

  • 23 Jul 2026 Merck Sharp & Dohme completes phase-I/II clinical trials in Renal cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Canada, Chile, France, Hungary, Israel, Netherlands, New Zealand, Poland, South Korea, South Korea, Spain, United Kingdom (PO) (NCT04626518)
  • 28 Feb 2026 Updated efficacy and adverse events data from a phase I/II KEYMAKER-U03 substudy 03B trial in Renal cell carcinoma presented at the 2026 Genitourinary Cancers Symposium (ASCO-GeCS-2026)
  • 05 Dec 2025 Merck Sharp & Dohme completes phase-I/II clinical trials in Oesophageal cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in in Turkey, Thailand, Switzerland, Singapore, Norway, Germany, Chile, Brazil, Japan, South Korea, France, Italy and Taiwan(IV) (NCT05342636)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top